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ABSTRACT
Monocytes/macrophages have recently been shown to
play a significant role in the pathogenesis of allergic
diseases. As the level of soluble CD14 (sCD14) in serum
is considered a marker of monocyte/macrophage acti-
vation, we measured the levels of sCD14 in allergic
asthma and atopic dermatitis (AD), along with acute
infectious and inflammatory diseases, to see its clinical
relevance. Serum samples were taken from patients
with acute infectious and inflammatory diseases, allergic
asthma, and atopic dermatitis. sCD14 was measured
with our own ELISA system and its level in each disease
was compared with normal controls as well as its
disease severity. sCD14 was elevated and correlated
with C-reactive protein in infectious and inflammatory
diseases (n = 26), confirming that it reflects inflam-
mation. sCD14 was also significantly increased both in
asthma (n = 94) and adult chronic AD (n = 22). In
asthmatic patients, those with higher sCD14 tended to
have more severe symptoms, but there was no statisti-
cal correlation between sCD14 and severity. In adult
chronic AD patients, a correlation between sCD14 and
disease severity was observed. However, sCD14 was
not elevated in infant AD patients (n = 18) irrespec-
tive of severity, suggesting differences in the degree
of monocyte/macrophage involvement in the patho-
genesis between adult chronic and infant AD. The levels
of sCD14 were shown to be upregulated in allergic
diseases and might be useful as a marker of mono-
cyte/macrophage involvement in allergic inflammation.
Key words: asthma, atopic dermatitis, CD14, inflam-
mation, macrophage, monocyte.
INTRODUCTION
Atopic asthma is regarded as an inflammatory disease
with secondary features that include edema, airway
smooth-muscle contraction, and obstruction of airways
by secretions.1 Atopic dermatitis (AD) is also an allergic
disorder with striking parallels to asthma but involving a
different regional sphere of immunologic and non-
immunologic influences.2 Although mast cells, T lympho-
cytes, and eosinophils have been considered to be of
particular importance,3 several studies have shown that
monocytes/macrophages may also play an important
role in these allergic diseases.2,4,5 Recently, evidence
has been accumulated to suggest the importance of
Fc e RI-expressing antigen-presenting cells including
monocytes in allergic immune response (for review, see
Bieber6).
CD14 is a 55 kDa glycoprotein found as a glycosyl-
phosphatidylinositol-anchored species on the surface of
monocytes and macrophages.7,8 CD14 was originally
found to bind lipopolysaccharide (LPS) and enhance
immune responses of cells to LPS,9 and recent evidence
suggests that CD14 also mediates responses to other bac-
terial molecules.10–13 CD14 is also found as an abundant
(1–3 m g/mL) soluble protein (sCD14) in human plasma.7,8
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Although the physiological role of sCD14 has not been
determined, it is known to be shed from the surface of
activated monocytes and has been considered as a
marker of monocyte/macrophage activation.14 In fact, a
growing number of reports have shown that the level of
sCD14 increases in inflammatory diseases in which
activated monocytes/macrophages may play an impor-
tant role, such as sepsis,15–18 HIV infection,19 autoimmune
diseases,20,21 and atopic dermatitis.22 Considering the fact
that allergic diseases have been regarded as inflammatory
diseases and that monocytes/macrophages may have
some role in the pathogenesis of allergy, we were
intrigued to measure the levels of sCD14 in asthma and




Blood samples for normal controls were taken from
20 healthy children (age range, 2 months–14 years;
median ± SD, 6.0 ± 5.3 years) and 19 healthy adults
(age range, 16–45 years; median ± SD, 27.6 ± 9.4
years) with no personal history or physical findings con-
sistent with allergic deseases.
Blood samples from 26 children (age range, 6 months–
14 years; median ± SD, 3.3 ± 3.5 years) with acute
infectious and inflammatory diseases were taken both at
the onset of the diseases and 1–2 weeks after the onset,
when the diseases were in the recovery phase. The dis-
eases included 10 upper respiratory tract infections due
to the influenza virus, two cases of tonsillitis due to
Streptococcus pyogenes, six lower respiratory tract infec-
tions due to bacteria such as Hemophilus influenza and
Streptococcus pneumonia, four bacterial enterocolitis,
and four Kawasaki disease.
Blood samples for asthma were taken from 94 patients
(age range, 6–20 years; median ± SD, 12.6 ± 3.5 years)
with atopic asthma based on the criteria for the disease
made by the Japanese Society of Allergology. Briefly,
asthma was diagnosed by clinical symptoms (cough, chest
tightness, wheezing and dyspnea), decrease and daily
variability of peak expiratory flow (if available), measure-
ments of allergic status and family history of allergic
diseases. In a randomly chosen subset of these patients,
eosinophil cationic protein (ECP) levels were also meas-
ured (47 patients; age range, 6–20 years; median ± SD,
11.8 ± 3.3 years).
For ECP samples, the methods for sample collection
were standardized to avoid influences by multiple para-
meters. Specifically, bloods were allowed to stand at room
temperature for 30 minutes to permit ECP release from
eosinophils, after which serum was collected, frozen and
stored until use. sCD14 levels and symptom scores were
compared for 18 selected patients whose symptom scores
for the past year before samples were taken had been
strictly evaluated (age range, 12–18 years; median ± SD,
14.7 ± 1.8 years). Symptom score was determined as
follows: symptoms were recorded four times per day by
patients, and 1, 3, 6, and 9 points were assigned to each
episode of stridor without dyspnea, mild attack, moderate
attack, and severe attack, respectively. Total yearly symp-
tom scores were determined by summing up the points for
the past one year. 
Serum samples for AD were taken from 22 adults (age
range, 18–33 years; median ± SD, 25 ± 4.4 years; seven
severe, nine moderate, and six mild) and 18 infants (age
range, 3–15 months; median ± SD, 7.5 ± 2.7 months;
six severe, seven moderate, and five mild) who fulfilled
the criteria for AD.23 Severity of AD was defined by the
definition of Rajka and Langeland.23 At the time of taking
the samples, all the adult patients with AD were in the
chronic stage, having had the condition for more than
3 years and exhibiting typical lichenified lesions, while the
duration of AD for all the infants was less than a year.
Informed consent was obtained for all blood samples,
either from parents or, when appropriate, from the
patients themselves.
ELISA for sCD14
The ELISA for sCD14 was performed essentially as
described by Detmers et al.24 with some modification. A
total of 96 well ELISA plates (Nunc, Denmark) were coated
with anti-CD14 mAb, AML2–23 (Medarex, Annandale,
NJ, USA), at 2.5 m g/mL in PBS as a capture Ab, and incu-
bated overnight at 4°C. The plates were then washed
with PBS containing 0.05% Tween-20 and were blocked
with blocking buffer, poly HRP diluent (Research Diagnos-
tics Inc., NJ, USA), for 1 h at room temperature. After
washing, the plates were incubated with serum samples
diluted x1000 or serially diluted standard recombinant
human CD14 (a gift from Dr H. Lichenstein, Amgen, CA,
USA) in blocking buffer for 2 h at room temperature. Each
sample and standard was run in duplicate. The plates
were then washed and incubated with 0.1 m g/mL biotiny-
lated anti-CD14 mAb 3C10 diluted in blocking buffer for
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2 h at room temperature.24 The plates were washed
again, then incubated with appropriately diluted poly
HRP streptavidin 20 (Research Diagnostics) for 1 h at 4°C.
The signal was detected using TMB (3,3¢ ,5,5¢ -tetramethyl
benzidine) and read at A450 in an ELISA reader. The
working range of the assay was 0.1–20 ng/mL with an
absorbance value range of approximately 0.1–2.0 meas-
ured at 450 nm. Highly reproducible data were obtained
from the same samples tested several times either in the
same or in different plates (data not shown).
Measurement of serum ECP
Measurement of serum ECP was done using a radio-
immunoassay kit (Kabi-Pharmacia Diagnostics, Sweden)
in duplicate according to the manufacturer’s instructions.
Immunohistochemistry
Skin biopsy specimens were taken from chronic active
lesions of adult AD with informed consent. Immuno-
enzymatic staining for CD14 was performed with Dako
Pap Kit (Dako Japan, Kyoto, Japan). Sections were first
treated with 3% hydrogen peroxide, and treated with
normal rabbit serum for 20 min. Sections were then incu-
bated at room temperature with anti-CD14 mAb, AML2–
23 (Medarex, Annandale, NJ, USA) or isotype-matched
control antibody for 30 min at a dilution of 1:20. Sections
were rinsed again, incubated with IgG fraction of rabbit
antiserum to mouse immunoglobulins for 30 min, rinsed,
and incubated with PAP (soluble horseradish peroxidase-
mouse antihorseradish peroxidase) complex for 20 min.
Sections were then incubated with the substrate solution
containing amino-ethylcarbazole (AEC) and hydrogen
peroxide. After the rinse with distilled water, the specimens
were counterstained with Mayer’s hematoxylin.
Statistical analysis
A software package (Statview, CA, USA) was used for
statistical analysis on a Macintosh computer. Differences
between groups were analyzed by the Mann–Whitney
U-test.
RESULTS
Normal levels of sCD14 in adults and children
We first evaluated the normal levels of sCD14 both in
adults and children in our assay. The mean ± SD of
sCD14 from children aged 1 month to 15 years was
0.89 ± 0.26 m g/mL, which was almost the same as that
in normal adults (0.73 ± 0.24 m g/mL) (Fig. 1). There
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Fig. 1 Serum levels of sCD14 in normal controls and in patients with allergic diseases. Se, severe; Mo, moderate; Mi, mild;
AD, atopic dermatitis; *, P < 0.01;**, P < 0.01; ***, P < 0.05.
was no age difference in the level of sCD14 in childhood
(data not shown).
Increase of sCD14 in infectious and
inflammatory diseases
We measured the sera of 26 cases with various infectious
and inflammatory diseases. sCD14 was significantly ele-
vated at the onset and then decreased in the recovery
phase, 1–2 weeks after the onset (Fig. 2). Levels of sCD14
were correlated with C-reactive protein (CRP) (r = 0.58,
P < 0.001), the most common marker of inflammation
(Fig. 3). These results confirm the validity of sCD14 as a
marker of inflammation. Levels of sCD14 were not corre-
lated with white blood cell counts or monocyte counts in
peripheral blood (data not shown), indicating that it
reflects activation, not the cell number, of monocytes.
Correlation of sCD14 with CRP was more prominent in
influenza virus infection (n = 10, r = 0.846, P < 0.001)
than in bacterial infection (n = 12, r = 0.41, P = 0.046)
or Kawasaki disease (n = 4, r = 0.56, P = 0.154).
Levels of sCD14 in atopic asthma
We then tried to see the clinical relevance of sCD14 in
allergic inflammation. We first evaluated the levels of
sCD14 in sera from 94 patients with atopic asthma. As
shown in Fig. 1, the levels of sCD14 in asthmatic patients
were significantly higher than those in normal controls
(1.86 ± 0.95, P < 0.01). These samples were taken
when there was no asthma attack or symptoms of infec-
tion, and CRP was not elevated in any samples tested,
indicating that sCD14 can be elevated in allergic inflam-
mation without the concomitant elevation of CRP. We also
compared sCD14 levels with ECP in 47 randomly chosen
samples and found that those two parameters were not
correlated (data not shown). We then selected 18 asth-
matic patients whose symptom scores for the past one
year had been strictly evaluated, and their sCD14 levels
and symptom scores were compared. There was no sta-
tistical correlation between these parameters (Fig. 4).
However, those with higher sCD14 levels had the ten-
dency to have higher symptom scores.
Levels of sCD14 in atopic dermatitis
We measured sCD14 levels in sera from 22 adults and
18 infants with AD (Fig. 1). Compared with normal con-
trols, the levels of sCD14 in adult chronic AD were signifi-
cantly elevated (P < 0.01). Moreover, sCD14 levels were
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Fig. 2 Serum levels of sCD14 in patients with acute infectious
and inflammatory diseases.
Fig. 3 Correlation between sCD14 and C-reactive protein
in acute infectious and inflammatory diseases. r = 0.58;
P < 0.001.
higher as the severity of AD became stronger. In contrast
to the levels in adults, sCD14 in infants with AD were not
elevated, irrespective of severity. Again, CRP was not ele-
vated in any samples with AD.
Immunohistochemistry of CD14 in chronic
AD lesions
Immuno-enzymatic staining for CD14 was performed to
the skin biopsy specimens from adult chronic AD lesions.
A typical example is shown in Figure 5. Marked accumu-
lation of CD14 was observed around the vessels in
dermis, suggesting that the CD14 molecule in the
lesional skin came from monocytes infiltrating into the
dermis through the vessels. No staining was observed
when control antibody was used instead of anti-CD14
(data not shown). In this assay, it was difficult to deter-
mine whether the stained CD14 is on the cell surface or
solubilized.
DISCUSSION
In this paper, we confirmed that sCD14 correlates with
CRP in acute infectious and inflammatory diseases, and
thus reflects inflammation. We further showed that
sCD14 is significantly elevated in allergic diseases such
as asthma and AD, although CRP is not elevated in these
diseases. As sCD14 has been considered a marker of
monocyte/macrophage activation, these data suggest
the significant contribution of monocyte/macrophage in
the pathogenesis of allergic inflammation. The mecha-
nisms for the elevation of sCD14 without the concomitant
elevation of CRP is yet to be evaluated. However, sCD14
in bronchoalveolar fluid has been shown to be elevated
after transbronchial allergen challenge, indicating that
sCD14 release can occur in a mechanism different from
that in infectious diseases.25,26
The role of mononuclear phagocytes in allergy has
not been fully described. However, several studies have
shown that monocyte/macrophages from asthmatic
patients are in an activated state and may orchestrate
immune reactions in asthma.27,28 Recently, Maurer et al.
showed elevated Fce RI expression on monocytes of atopic
individuals,29 and that Fce RI on atopic monocytes medi-
ates IgE-dependent allergen presentation.30 Several other
reports have also shown that antigen presenting cells
including monocytes/macrophages may play a role
through Fce R I expressed on these cell.6 These Fce R-
dependent mechanisms may be one way of monocyte/
macrophage involvement in allergic inflammation. Evi-
dence of monocyte/macrophage involvement in atopic
dermatitis had come from studies showing that mono-
cytes from these patients exhibit: (i) priming for super-
oxide generation;31,32 (ii) elevated phosphodiesterase
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Fig. 4 Relationship between sCD14 and symptom score/year
in patients with allergic asthma. r = 0.20.
Fig. 5 Immunohistochemical staining of adult chronic atopic
dermatitis lesion. Immunohistochemical staining for CD14 was
performed as described in Methods.
activity which is linked to elevated secretion of IL-10 and
prostaglandin E2;33,34 and (iii) non-responsiveness to IL-4-
induced apoptosis which may contribute to the chronic
inflammation.35 Our data are consistent with these find-
ings, as sCD14 is considered a marker of monocyte/
macrophage activation.
In asthmatic patients we could not find a strict corre-
lation of sCD14 with disease severity, as defined by
symptom score, although there was a tendency for those
with higher sCD14 to have higher symptom scores. Larger-
scaled prospective studies would be necessary to further
evaluate the meaning of sCD14 in asthma. In the mean-
time, sCD14 was not correlated with ECP. As it is known
that serum ECP reflects activation of eosinophils,36,37 this
lack of correlation suggests that sCD14 levels have no
direct relation to the status of eosinophils.
A clear relationship of sCD14 with disease severity was
found in adult chronic AD. This is consistent with Wüthrich
et al. and suggests significant involvement of monocytes/
macrophages in the pathogenesis of AD.22 In contrast to
the levels in adults, sCD14 in infants with AD were not
elevated, irrespective of severity. The reason for this differ-
ence is not clear, but several possibilities exist. Disease
duration may contribute since histologic features of AD
depend on the acuity, and macrophages have been
shown to dominate in the dermal mononuclear cell infil-
trate in chronic lichenified lesions that are frequently seen
in adult patients.2 Consistent with these observations, it
has been shown that in situ expression of interferon-g , the
main activator of monocytes/macrophages, is linked to
the clinical course of AD,38 and that interferon-g expres-
sion has major pathogenic relevance for the chronic
phase of AD.39 Alternatively, differences in the allergens
that exacerbate the disease may contribute to the dif-
ference between adults and infants. Some studies have
shown that food allergens can exacerbate skin rashes in at
least a subset of patients with AD, especially children,
while the majority of patients, particularly adults, do not
have food allergy and alternatively, inhalation or contact
with aero-allergen may play a role.2 In fact, all AD infants
in our study had a positive reaction to egg white and no
reaction to aero-allergens, while most adult AD patients
had a positive reaction to house dust mite and no reaction
to food allergens, as determined by radio-allergosorbent
assay (data not shown). These differences may cause
different degree of involvement of monocyte/macrophage
in the pathogenesis of AD.
In a separate experiment, we confirmed the existence of
CD14 molecule at the dermis of skin biopsy specimens
with AD by immunohistochemical staining with anti-CD14.
We have recently showed the existence of amphiphilic
molecules from Staphylococcus aureus (S. aureus) that bind
CD14 and stimulate inflammatory cells.10,11 As S. aureus is
found in over 90% of AD skin lesions,2 CD14 in lesional
skin may contribute to exacerbation of the disease by
interacting with such S. aureus molecules and activating
inflammatory cells migrating to the lesion.
There are many questions unanswered regarding
sCD14. First, it remains to be evaluated how the level of
sCD14 is regulated in serum, although several studies
have shown that IL-4 and granulocyte macrophage-
colony stimulating factor (GM-CSF) both downregulate
CD14 expression and release.40,41 CRP, the commonest
and most useful marker of inflammation, is produced
as an acute phase protein from hepatocytes stimulated
with inflammatory cytokines such as IL-6.42 It may be of
interest to determine whether the same cytokines can
upregulate sCD14 as well. Second, it is yet to be defined
which types of cells (other than CD14-positive cells) can
produce sCD14. Our unpublished data suggests that
human hepatocytes also express and secrete CD14 and
studies in mice show many tissues may express CD14
upon stimulation.43 Finally, the physiological role of
sCD14 has not been determined. In this respect, a role of
sCD14 as a lipid transfer protein has been recently pro-
posed by Yu et al.44 Evaluation of regulatory mechanisms
and physiological function of sCD14 will shed more light
on the importance and the meaning of the level of sCD14.
Our data strongly suggest the involvement of monocytes/
macrophages in the pathogenesis of allergic diseases.
Further evaluation of the role of monocyes/macrophages
and sCD14 in allergic diseases may be a fruitful area
of study.
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